Sanofi (SNY)
| Market Cap | 113.21B -10.1% |
| Revenue (ttm) | 54.85B +5.5% |
| Net Income | 9.17B +40.5% |
| EPS | 7.48 +43.6% |
| Shares Out | 1.21B |
| PE Ratio | 12.34 |
| Forward PE | 9.38 |
| Dividend | $1.60 (3.42%) |
| Ex-Dividend Date | May 9, 2025 |
| Volume | 2,922,464 |
| Open | 47.37 |
| Previous Close | 47.53 |
| Day's Range | 46.72 - 47.50 |
| 52-Week Range | 43.32 - 55.73 |
| Beta | 0.32 |
| Analysts | Buy |
| Price Target | 58.00 (+23.99%) |
| Earnings Date | Apr 23, 2026 |
About SNY
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for onc... [Read more]
Financial Performance
In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for SNY stock is "Buy." The 12-month stock price target is $58.0, which is an increase of 23.99% from the latest price.
News
3 Healthcare Stocks That Pay You a Dividend While You Wait for a Recovery
Some shareholders are waiting for healthcare stocks to rebound. As they wait, some companies pay out dividends with meaningful yields that make that waiting easier.
Press Release: Sanofi successfully prices 2.3 billion of bond issue
Sanofi successfully prices 2.3 billion of bond issue Paris, April 24, 2026 - Sanofi announces that it has successfully priced its offering of €2.3 billion of notes across 3 tranches: €1,000 million...
Press Release: Sanofi's Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses
Sanofi's Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses
Sanofi Posts Higher Sales Amid Leadership Transition
Sales rose 14% to €10.51 billion at constant currency, boosted by new launches and recent acquisitions.
Sanofi's first quarter earnings edges past estimates ahead of CEO change
French drugmaker Sanofi on Thursday reported first-quarter profit and revenue above market expectations, boosted by resilient demand for its blockbuster asthma and eczema drug Dupixent.
Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children
Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children Expanded approval includes children aged one year and above with stage 2 T1D to delay the onset of st...
Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US
Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US Paris, April 22, 2026. The US Food and Drug Administration (FDA) has extended by up to three months the target a...
Press Release: Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
Press Release: Sanofi's lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP
Sanofi's lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP The AIRCULES phase 2b study achieved its primary and key secondary endpoints in modera...
Press Release: Sanofi's Rezurock approved in the EU to treat chronic graft-vs-host disease
Sanofi's Rezurock approved in the EU to treat chronic graft-vs-host disease Rezurock is now approved in the EU for adults and children aged 12 years and older with chronic GVHD, providing a new medici...
Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
EU regulator backs Sanofi's injectable version of blood cancer drug
French drugmaker Sanofi said on Friday the European Medicines Agency has recommended the approval of a subcutaneous version of its blood cancer drug administered through an on-body injector.
Press release: Availability of the Q1 2026 aide-mémoire
Availability of the Q1 2026 aide-mémoire Paris, France – March 24, 2026. Sanofi announced today the availability of its Q1 2026 aide-mémoire on the "Investors" page of the company's website: First qua...
Press Release: Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment
Kali Therapeutics said on Monday it has entered into a licensing agreement with French drugmaker Sanofi to develop the privately held firm's experimental treatment for several autoimmune diseases.
Sanofi launches innovation and operation centre in China
French drugmaker Sanofi launched an innovation and operation centre in the southwestern Chinese city of Chengdu on Thursday, the company said in a statement released on its Chinese social med...
TrumpRx lists many medicines at prices higher than paid in UK
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those ...
Mirecule Expands Strategic FSHD Collaboration with Sanofi
GAITHERSBURG, Md.--(BUSINESS WIRE)--Mirecule expands strategic collaboration with Sanofi on advancement of best-in-class ARC treatment of Facioscapulohumeral Muscular Dystrophy (FSHD).
Press Release: Sanofi's venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease
Sanofi's venglusta t earns Breakthrough Therapy designation in the US for type 3 Gaucher disease Paris, March 18, 2026 . The US Food and Drug Administration (FDA) has granted Breakthrough Therapy des...
Big drugmakers must face US overcharge claims on medications for low-income patients
A U.S. appeals court on Tuesday revived a whistleblower lawsuit accusing four large drugmakers of defrauding the federal and state governments out of hundreds of millions of dollars by overcharging ...
The Big 3: PR, ELF, SNY
From oil, beauty, and therapeutic resource stocks, @ElliottWaveTrader's Tammy Marshall turns to three companies she sees as unsung market opportunities. The Fibonacci Princess offers insight and exa...
Sanofi: Information concerning the total number of voting rights and shares - February 2026
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement g...
Brazil drugmaker EMS eyes overseas deals after buying Sanofi unit
Brazilian drugmaker EMS is open to fresh acquisitions to expand internationally after inking a major deal to buy Sanofi's Brazil-based generic drugmaker Medley, and is gearing up to launch its own se...
Press Release: Sanofi's Board of Directors proposes the appointment of Christel Heydemann as an independent director
Sanofi's Board of Directors proposes the appointment of Christel Heydemann as an independent director